Status: Recruiting
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX-2843 in 28 day cycles at predefined dose cohorts.
Participants needed: 50
Trial details
Phase: Phase 1Age: 12+Biological sex: AllType: InterventionalSponsor: Meryx, Inc.Updated: Jan 8, 2026Locations: 3
Eligibility criteria
Patient is a male or female at least 12 years of age. [+11]
Patient has diagnosis of acute promyelocytic leukemia (or AML M3). [+21]